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A cholinergic-sympathetic pathway primes
immunity in hypertension and mediates
brain-to-spleen communication
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The crucial role of the immune system in hypertension is now widely recognized.
We previously reported that hypertensive challenges couple the nervous drive with immune
system activation, but the physiological and molecular mechanisms of this connection
are unknown. Here, we show that hypertensive challenges activate splenic sympathetic
nerve discharge to prime immune response. More specifically, a vagus-splenic nerve drive,
mediated by nicotinic cholinergic receptors, links the brain and spleen. The sympathetic
discharge induced by hypertensive stimuli was absent in both coeliac vagotomized mice and
in mice lacking a7nAChR, a receptor typically expressed by peripheral ganglionic neurons.
This cholinergic-sympathetic pathway is necessary for T cell activation and egression on
hypertensive challenges. In addition, we show that selectively thermoablating the splenic
nerve prevents T cell egression and protects against hypertension. This novel experimental
procedure for selective splenic denervation suggests new clinical strategies for resistant
hypertension.
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D
espite the wide spectrum of antihypertensive medications
currently available, a significant proportion of patients
still have poorly controlled blood pressure and,
consequently, resistant hypertension1–3. In the first half of the
past century, the Mosaic Theory of Hypertension proposed that
many factors, including genetics and environment as well as
nervous, mechanical and hormonal perturbations, interplay to
raise blood pressure4. Because the aetiology of hypertension is
multifaceted, its solution must involve more than a single
anatomical organ.
In the last decade, immunity emerged as a crucial player in
hypertension: immune cells infiltrate the vessel walls and kidneys
of hypertensive animals, and mice without lymphocytes are
protected from angiotensinII (AngII)-induced hypertension5–9.
Despite growing awareness of immune cells’ role in hypertension,
blood pressure control has been considered primarily the work of
the autonomic nervous system10. The sympathetic nervous
system, by contrast, has historically been thought to influence
blood pressure control via regulation of key physiological
parameters including heart rate, vascular tone and renal sodium
excretion3. Clinically, sympathetic innervation of the kidney has
been seen as the cause of hypertension, and renal denervation has
been regarded as an intriguing new approach to treating
uncontrolled high blood pressure11–13.
The autonomic nervous system also regulates of immunity14–17,
though its role is often overlooked. Previously, we have found
that placental growth factor (PlGF), an angiogenic growth
factor belonging to the vascular endothelial growth factor
(VEGF) family, links the nervous drive to immune system
activation7. We performed a coeliac ganglionectomy to selectively
disrupt sympathetic innervation of splanchnic circulation and
found that PlGF activation, immune system recruitment and
increased blood pressure depend on this pathway7. Interestingly,
preliminary studies indicated that splanchnic innervation would
impact hypertension18. However, two main questions remain
unanswered: (i) which splanchnic nervous compartment is
responsible for these effects on immunity and blood pressure
regulation and (ii) how is the brain-to-splanchnic compartment
connection established at the onset of hypertension.
Results
Hypertensive stimuli activate splenic nerve discharge. Although
chronic AngII has been shown to be a potent driver of splanchnic
circulation18, we do not yet know which downstream nervous
district is engaged by hypertensive stimuli to increase blood
pressure. The chronic effects of AngII are mediated by brain
signals transmitted via the peripheral networks19. Indeed, lesions
in central nervous system organs, which are able to sense
peripheral challenges, prevent AngII infusion from raising
blood pressure19. Taken together, these connections suggest
that peripherally-delivered hypertensive stimuli activate a nervous
drive in the brain that is conveyed through splanchnic circulation.
Given that immune system activation in hypertension depends
on the same pathway, we hypothesized that the splenic nerve
could be the splanchnic innervation connecting the brain and
immune cells.
To test this idea, we established a procedure for recording
sympathetic nerve activity (SNA) in mice. First, we validated
splenic nerve SNA (SSNA) recording by inducing reflex responses
to blood pressure changes. We pharmacologically manipulated
blood pressure with sodium nitroprusside and phenylephrine to
500
120
100
80
60
40
20B
P 
(m
mH
g)
120
100
80
60
40
20BP
 (m
mH
g)
500
Vehicle
AngII
Postmortem
1 s
1 min
1 s
SS
NA
 (μ
V) 250
250
0
500
500
SS
NA
 (μ
V) 250
250
0
500
500
200 3.0
2.5
2.0
1.5
1.0
Am
pl
itu
de
 g
ai
n
150
Fi
rin
g 
 fr
eq
ue
nc
y
(sp
ike
s/1
0 m
in)
100
50
0
Vehicle AngII Vehicle AngII
*****
SS
NA
 (μ
V) 250
250
0
a b c
d e
Figure 1 | AngII activates discharge of the splenic nerve. (a,b) Representative raw signals of SSNA in a time bin of 10 min in (a) show a significantly
increased nerve discharge in AngII-infused mice as compared with vehicle. Raw signal of residual SSNA during postmortem was used to identify the signal
threshold level for each recording. In (b) it is represented an enlarged view of 10 s of SSNA raw signal from the red window in a. (c) Blood pressure (BP)
monitoring during SSNA recording excluded hemodynamic effects. (d) Firing frequency, represented by the mean number of spikes in a time bin, was
significantly higher in AngII-infused mice as compared with vehicle (vehicle nmice¼ 8 and AngII nmice¼ 10; independent samples Student’s t-test,
t(16)¼ 4.697, ***Po0.001). (e) Analysis of mean amplitude gain of spikes showed that AngII-infused mice had also increased SSNA in the pattern of
burst amplitude as compared with vehicle (vehicle nmice¼8 and AngII nmice¼ 10; independent samples Student’s t-test, t(9)¼  3.120, **Po0.01).
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evaluate typical SNA reflex responses (Supplementary Figs 1
and 2). We found that SSNA increased quickly in response to
lowered blood pressure, as expected for sympathetic activity
(Supplementary Fig. 1a–c). To further assess nerve activity, we
evaluated synchronous sympathetic bursts. Analysis of SSNA
showed that most nerve bursts synchronized with raw blood
pressure signal (Supplementary Fig. 1d,e), a result that is
consistent with the semirhythmic SNA observed in nerves
in nearby compartments, including the splanchnic10,20–22.
Ganglionic blockade with hexamethonium abolished SSNA
activity (Supplementary Fig. 1f), which overlapped the residual
postmortem recording (Supplementary Fig. 1g) that was used
thereafter as the positive action potential threshold. As expected,
the opposite response was observed when mice were challenged
with phenylephrine to acutely increase blood pressure. Indeed,
the SSNA, although similarly pulse synchronous, was markedly
reduced (Supplementary Fig. 2a–g).
After validating the direct SSNA recording method, we tested
whether chronic AngII infusion activates SSNA to modulate
subsequent T cell activation. To avoid the potentially confound-
ing effects of increased blood pressure itself, we analyzed mice 3
days after starting AngII infusion, when blood pressure has not
yet significantly changed (Supplementary Fig. 3). To find the
appropriate time point for examining the connection between
nervous drive and immune activation, we performed a time
course analysis of T cell recruitment in target organs. After 3
days, we could detect T cells in the aortas (Supplementary
Fig. 4a,b) and kidneys (Supplementary Fig. 4c,d) of AngII-infused
mice.
Next, we used a bipolar electrode to record SSNA in splenic
nerve bundles in mice infused with either AngII or Vehicle
(Fig. 1). A representative recording of splenic nerve discharge
clearly shows increased rhythmic SSNA bursts above the
background noise, as defined by the postmortem recording
(Fig. 1a,b). Simultaneous blood pressure recording demonstrated
animal stability during the procedure (Fig. 1c). Changes in SSNA
included increases in either the number of sympathetic bursts or
the amplitude of individual bursts. We found that AngII-infused
mice had significantly higher SSNA, measured both as firing
frequency (Fig. 1d) and as mean amplitude gain (Fig. 1e), than
controls.
To determine if the increased SSNA was a selective response to
AngII, we also performed experiments with deoxycorticosterone
acetate (DOCA)-salt hypertensive mice, a model characterized
by increased AngII levels in the brain and reduced peripheral
renin–angiotensin system (RAS) activation23. As in the
experiments detailed above, in this model we studied mice at
the beginning of blood pressure increase (Supplementary Fig. 5)
and again found elevated SSNA (Fig. 2a–c). Quantitative analysis
confirmed that SSNA activation is similar in DOCA-salt-treated
mice and AngII-hypertensive mice (Fig. 2d,e), thereby suggesting
the brain-to-splenic nerve drive is a common pathway for
hypertensive challenges that are sensed by the brain and
consequently lead to elevated blood pressure.
The vagal-coeliac-splenic connection mediates hypertension.
Sympathetic innervation of the spleen has been recognized as a
crucial mechanism for modulating immune cell functions24–26.
For many years, autonomic innervation of immune organs
did not seem relevant to cardiology, but current evidence for
immunity’s vital role in blood pressure regulation necessitates
investigating neuro-immune reflexes in hypertension. Sympathetic
and parasympathetic innervations of the splanchnic organs have
been traditionally regarded as anatomically separate along their
peripheral routes. If the innervations are indeed separate, the
splenic nerve should be activated by a pre-ganglionic neuron in
the paravertebral ganglia chain that connects to the inter-
mediolateral grey column in the spinal cord. However,
immunologists have identified a cholinergic anti-inflammatory
reflex that is mediated by the vagus nerve’s coeliac branch and
specifically targets splenic innervation during septic challenges24–27.
To investigate whether and how vagal signals could affect
splenic nerve activity during hypertensive challenges, we
performed cervical vagotomy while recording SSNA (Fig. 3a–c).
Cervical vagotomy completely prevented AngII from activating
the splenic nerve (Fig. 3a,b). These results indicate that
AngII-induced splenic nerve activation is mediated by the
cervical vagus nerve. Unexpectedly, we found no reduction in
residual SSNA gain amplitude after both cervical and coeliac
vagotomy (Fig. 3c), a result that suggests hypertensive stimuli use
different sympathetic pathways for SSNA firing frequency and
individual burst amplitude. As previously reported concerning
the regulation of other organs10, our results indicate that a
specific brain cell network produces rhythmical discharges in the
splenic nerve through the vagus connection. Conversely, other
central nervous system cell groups regulate splenic nerve gain
amplitude independently from the vagus nerve. To further
uncover the relative contributions of the vagus nerve’s afferent
versus efferent arms, we performed a coeliac vagotomy that also
completely inhibited AngII-induced SSNA (Fig. 3d,e), still with
no effect on the gain amplitude of splenic nerve activity (Fig. 3f).
In addition, we analyzed the chronic response to AngII in mice
with left coeliac vagotomy. Inhibiting vagus nerve efferents
hampered the blood pressure increase typically induced by AngII
(Fig. 4a,b) as well as the T cell egression (Fig. 4c,d).
Overall, these results support our proposal that, although the
vagus nerve has been considered paradigmatic for para-
sympathetic modulation of blood pressure28, it also activates
the splenic nerve under hypertensive challenges. This previously
unknown aspect of hypertension may indicate that completely
different pathophysiological conditions, such as sepsis and
hypertension, can affect the same neuro-immune connection.
a7nAChR at the intersection of the vagus and splenic nerves.
Mammals regulate synaptic transmission across sympathetic and
parasympathetic ganglia via nicotinic acetylcholine receptors
(nAChR), which can assemble in various stoichiometries and
therefore have many functions29. One nAChR, the a7 subunit,
can form homomeric pentamers that mediate excitatory
postsynaptic currents. Interestingly, a7nAChR also participates
in the cholinergic anti-inflammatory reflex and, though initially
discovered as a modulator of macrophage function, has been
shown to couple the vagus-splenic connection at the neuronal
level25,26. Yet a7nAChR is not required for the parasympathetic
modulations exerted by the vagus nerve in typical cardiovascular
parameters such as heart rate30. To our surprise, a7nAChR KO
mice infused with AngII had significantly inhibited SSNA firing
frequency (Fig. 5a–d), which suggests the drive was hampered
before reaching the splenic nerve. As observed in vagotomized
mice, AngII infusion did not alter SSNA amplitude gain in
a7nAChR KO mice (Fig. 5e). It may be that different SNA
patterns can evoke different neurotransmitter responses10.
Because the AngII-infused vagotomized and a7nAChR KO mice
showed the vagus-splenic connection affects firing frequency but
not amplitude gain, we asked which pattern is relevant for
noradrenaline release in the spleen. Since AngII increases
noradrenaline in the spleen through the activation of tyrosine
hydroxylase7, we examined this response in AngII-infused
a7nAChR KO mice and found that both noradrenaline content
(Supplementary Fig. 6a) and tyrosine hydroxylase staining
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(Supplementary Fig. 6b) were significantly inhibited as compared
with WT mice. In particular, the adrenergic fibres typically
innervating the marginal zone of the spleen, evidenced by the
CD169 antigen, were almost absent in a7nAChR KO mice
(Supplementary Fig. 6b). Further, AngII challenge in a7nAChR
KO mice produced neither the increased blood pressure typically
observed in WT mice (Fig. 6a,b) nor the expected T cell egression
(Fig. 6c,d). Overall, these data support the existence of a
vagus-splenic nerve connection that is recruited by hypertensive
stimuli and mediated by a7nAChR.
Splenic nerve ablation prevents immune activation on AngII.
To define the relationship between SSNA and blood pressure
rising in response to hypertensive stimuli, we established a
procedure to denervate selectively splenic nerves (SDN) by
thermoablation (Fig. 7a). Our first step was to verify that the
procedure itself would not damage the artery. Ultrasound
Doppler imaging revealed that SDN did not affect the normal
pulse wave of the splenic artery (Fig. 7b). Moreover, microCT
angiography after splenic denervation showed splenic artery
integrity and consequently normal perfusion of the spleen
(Fig. 7c,d). To evaluate SDN efficacy, we injected a retrograde
neurotracer into the spleen to label coeliac ganglion neurons
(Fig. 8a). This procedure confirmed interrupted nerve trafficking
between the central nervous system and spleen. In addition,
tyrosine hydroxylase innervation was markedly reduced in the
splenic arteries of SDN mice, as compared with sham (Fig. 8b), as
was splenic noradrenaline (Fig. 8c). To demonstrate the selectivity
of the procedure for the splenic nerve, we measured ipsilateral
kidney noradrenaline content, which was comparable in SDN and
sham mice (Fig. 8d), thereby affirming there were no
confounding off-target SDN effects.
Next, we infused SDN and sham mice with AngII for 28 days
using osmotic minipumps to elevate sympathetic nervous system
activation in the spleen, as shown by increased tyrosine
hydroxylase staining (Supplementary Fig. 7a). SDN mice were
protected from elevated sympathetic nervous system activity in
the marginal zone of the spleen, delineated by the CD169 antigen
(Supplementary Fig. 7a). More importantly, SDN mice were
significantly protected from the increased blood pressure induced
by chronic AngII that is typically observed in sham mice
(Fig. 9a,b; Supplementary Fig. 7b,c). Similar results were obtained
with both radiotelemetry (Supplementary Fig. 7b,c) and tail-cuff
measurements (Fig. 9a,b). We then asked whether this effect
could be due to a modulating function of SSNA on splenic T cells,
which are known to be activated by hypertensive challenges,
before deployment toward target organs5–7. SDN hampered
AngII-induced T cell egression from the splenic reservoir, as
shown by the total CD3þ T cell content and area in the white
pulp (Fig. 9c,d). Indeed, AngII infusion did not reduce T cell
content in mice with SDN but did in sham mice (Fig. 9c,d). We
also evaluated whether the lack of T cell egression could be caused
by failed T cell co-stimulation activation in the absence of an
intact splenic nerve. Mice with SDN were protected from
AngII-induced CD86 expression (Fig. 9e), the typical hallmark
of T cell co-stimulation and hence a key indicator of full
activation for target organ colonization in hypertension6,7. We
next assessed T cell infiltration in target organs by flow cytometry
and found that AngII-SDN mice were significantly protected
from CD8þ T cell infiltration in the aorta (Fig. 10a) and kidneys
(Fig. 10b,c) in terms of both total cells and the number of cells
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Figure 2 | Activation of splenic nerve activity is a common response to hypertensive stimuli. (a–c) DOCA-salt hypertensive challenge significantly
increased splenic nerve discharge, in a similar way to that observed in AngII-infused mice, as shown by the representative raw signals of SSNA in a time bin
of 10 min (a) and a particular of 10 s from the red window in b. Residual SSNA during postmortem (lower panel in a) and BP monitoring (c) are shown as
well. (d) DOCA-salt induced a significant increase in firing frequency, expressed as the mean number of spikes in a time bin, as compared with mice
receiving placebo (Placebo nmice¼ 6 and DOCA-salt nmice¼ 7; independent samples Student’s t-test, t(11)¼  9.654, ***Po0.001). (e) DOCA-salt-treated
mice display a significant higher mean amplitude gain of spikes, as compared with mice receiving placebo alone (Placebo nmice¼6 and DOCA-salt
nmice¼ 7; independent samples Student’s t-test, t(11)¼  5.977, ***Po0.001).
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primed with markers for homing (CD8þ CD44þ cells) and
activation (CD8þ CD69þ cells). Similar results were found
for CD4þ T cell infiltrates (Fig. 10a–c). These data were
also confirmed by immunohistochemical analyses of the
aorta (Supplementary Fig. 8a–d) and kidneys (Supplementary
Fig. 9a–d).
Discussion
Our results demonstrate that hypertensive challenges exploit a
cholinergic-sympathetic drive, realized through a vagus-splenic
nerve connection, to activate the T cells that eventually migrate to
target organs and contribute to blood pressure regulation. We
show that stimuli like chronic AngII and DOCA, which are
sensed by the circumventricular organs in the brain to induce
hypertension19,23, activate potent splenic nerve discharge. We
also report that SSNA depends on an intact vagus nerve efferent
that terminates in the coeliac plexus ganglia where the
catecholaminergic fibres of the splenic nerve originate. We
further demonstrated that the vagal-coeliac-splenic nerve
connection regulating blood pressure is mediated by a7nAChR,
similar to dynamics previously described in endotoxemia26.
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Figure 3 | Efferent vagus nerve resection blocks the SSNA induced by hypertensive stimuli. (a) Mice infused with AngII were subjected to cervical
vagotomy (VagX) while recording SSNA. As shown by the representative raw signals of SSNA, cervical VagX completely abolishes splenic nerve activity.
(b) Analysis of firing frequency confirmed the inhibitory effect of cervical VagX on AngII-induced SSNA (nmice¼ 5; paired samples Student’s t-test,
t(4)¼8.524, ***Po0.001). (c) Conversely, no effect of cervical VagX on the mean amplitude gain of spikes was observed, suggesting that this pattern of
SSNA was regulated by pathways different from the vagus nerve (nmice¼ 5; paired samples Student’s t-test, t(4)¼  2.764, P¼0.051). (d) To verify
whether the effect was due to the afferent or efferent branch of the vagus nerve, a further group of AngII-infused mice underwent coeliac vagotomy (VagX)
while recording SSNA. Even in this case, splenic nerve activity was completely inhibited by coeliac VagX. (e) Analysis of firing frequency confirmed the
inhibitory effect of coeliac VagX on AngII-induced SSNA (nmice¼ 5; paired samples Student’s t-test, t(4)¼ 11.059, ***Po0.001). (f) Yet, no effect of coeliac
VagX on the mean amplitude gain of spikes was observed, further supporting that this pattern of SSNA was regulated by pathways different from the vagus
nerve (nmice¼ 5; paired samples Student’s t-test, t(4)¼  1.518, P¼0.204).
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Figure 5 | a7nAChR is necessary to the activation of SSNA on hypertensive challenges. (a–c) The representative raw signals of SSNA in a time bin
(a) and in an enlarged particular of 10 s (b) show that a7nAChR KO mice have a reduced response to AngII infusion, as compared with WT controls.
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to that of WTmice (WT and a7nAChR KO nmice¼ 7; independent samples Student’s t-test, t(12)¼0.572, P¼0.578).
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Taken together, our findings—particularly our selective
denervation of the splenic nerve—have important translational
implications. Mice with splenic denervation were protected from
hypertension through impeded T cell activation, egression from
the spleen and consequent infiltration of target organs. These
results provide a rationale for investigating novel therapeutic
strategies based on splenic denervation to treat hypertension.
Historically recognized as a crucial player in hypertension, the
sympathetic overdrive promotes the initial blood pressure surge
in the early clinical stages of the disease and helps maintain
elevated blood pressure levels3,10. Moreover, constant adrenergic
overactivation is known to contribute, over time, to end-organ
damage caused by chronic hypertension and metabolic
abnormalities often observed in hypertensive patients.
Researchers have sought to understand the mechanisms and
effects of renal sympathetic nerves in hypertension31. Indeed, it is
now widely accepted that, under hypertensive conditions, this
system changes in pathological ways that contribute to alterations
in sodium reabsorption and thus negatively influence blood
pressure control3,10,31. Yet the results of clinical trials on renal
denervation remain controversial11–13, lending support to the
hypothesis that there may be other mechanisms contributing
to the impact of constant sympathetic overactivation in
hypertension. Hence, we sought to pursue selective splenic
denervation to decipher the immune system’s role in
hypertension. Although a simple neurectomy could in principle
prove the same concepts and provide results, selective
denervation obtained by thermoablation has clinical potential
for patients for whom the renal denervation has failed. Our
results strongly suggest splenic denervation may be a useful tool
in treating resistant hypertension in humans.
Abundant research has confirmed that the immune system
plays a key role in hypertension. Yet the process by which a
hypertensive challenge signals the immune system has remained
largely unclear. Intriguingly, even as researchers in the field of
hypertension began dissecting the role of the immune system,
immunologists of the same period discovered that neural circuits
can modulate immune cells15,32. Meanwhile, decades of studies
focusing on the neurophysiological basis and broader effects of
the inflammatory reflex converged on the spleen. Action
potentials are transmitted from the vagus nerve to the coeliac
ganglion, where the splenic nerve originates, and activated
adrenergic splenic neurons can regulate a specific T cell subset
in splenic white pulp. In the spleen, we now know, neural signals
deal with immunity directly33,34. We are beginning to understand
the complex relationship between the nervous system and
immunity.
As researchers continue to decipher these connections, nervous
circuits’ largely undiscussed role in blood pressure regulation10
will become increasingly important. On the basis of our results,
it is tempting to speculate that sympathetic overactivity in
hypertension has effects beyond the kidney and baroreflexes. The
novel concept that the autonomic nervous system can have long-
term effects on cardiovascular pathologies through immune
system regulation requires us to significantly rethink the role of
the autonomic nervous system14. Interestingly, it is well known
that immune organs, and particularly the spleen, are directly
innervated by the sympathetic nervous system7,35. In addition,
the autonomic system may be a powerful regulator of immunity:
although AngII has been shown to be responsible for a variety of
actions that may contribute to the development of hypertension,
several milestone papers demonstrate that AngII also activates the
peripheral sympathetic nervous system and affects immune
responses19. Intracerebral ventricular AngII infusion increases
central sympathetic nerve activation and enhances the immune
response in the periphery36. These findings are particularly
important because they demonstrate that AngII-induced effects
on both hypertension and immune system activation are not
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caused by direct AngII influence on the vasculature and immune
cells, thus suggesting that central signals may be integrated by the
immune system to drive hypertension.
We believe the results presented in this paper are significant
because they reveal, for the first time, a previously unknown
sympathetic pathway in hypertension. The brain-to-spleen
connection’s realization through a cholinergic-sympathetic
nervous drive resembles the cholinergic anti-inflammatory
pathway that is protective when activated by electrically
stimulating the vagus efferent during endotoxemia24–27. So far,
this pathway has been primarily considered a way for the nervous
system to modulate immune response to bacterial toxins.
More specifically, vagus stimulation during septic shock
determines the coupling of cholinergic pre-ganglionic neurons
and postganglionic sympathetic nerves, linkages that
are ultimately responsible for attenuating splenic TNFa
production24–27.
a7nAChR has been well characterized as the molecular
mediator of the cholinergic anti-inflammatory pathway and
therefore integral to the vagus nerve/sympathetic drive in the
splenic district26,34. Indeed, a7nAChR can be found in several
tissues, including the brain, ganglia, immune cells and so on.
Our experiments showed that a7nAChR KO mice are
protected from AngII-induced hypertension. Because
a7nAChR is a demonstrable mediator of the cholinergic anti-
inflammatory pathway expressed in cytokine-producing splenic
macrophages25,34 but also integrates the sympathetic and
parasympathetic systems in presynaptic neurons of the splenic
nerve26, we sought to understand where a7nAChR acts in
hypertension. That a7nAChR KO mice had markedly inhibited
AngII-elicited SSNA supported the idea that a7nAChR plays a
role in mediating autonomic integration among parasympathetic
and sympathetic drives in the coeliac ganglion (upstream from
the splenic sympathetic drive). Interestingly, vagus nerve
stimulation was recently shown to mediate protection from
kidney ischemia-reperfusion injury through a7nAChR in
splenocytes37. Lastly, our findings highlight the possibility
that cholinergic anti-inflammatory pathway activation during
endotoxemia may be also hemodynamic and therefore relevant to
fighting the hypotensive shock that is one of the fatal
complications of sepsis.
Methods
Animals and drugs. All animal handling and experimental procedures were
performed according to European Community guidelines (EC Council Directive
2010/63) and the Italian legislation on animal experimentation (Decreto Legislativo
D.Lgs 26/2014). All efforts were made to minimize suffering, and the principles of
Replacement, Reduction and Refinement (that is, the ‘three Rs’) were applied to all
experiments.
C57Bl/6J male mice, aged 8-12 weeks, were purchased from Jackson Laboratory
and used in all experiments. Chrna7 (a7nAChR) knockout and WT littermates
(stock number 003232, Jackson Laboratory) were used where indicated. Mice were
housed in an air-conditioned room (temperature 21±1 C, relative humidity
60±10%), with lights on from 06:00 to 18:00, and had sawdust as bedding, pellet
food and tap water ad libitum. After surgical procedures, mice were housed in
recovery boxes (temperature 37 C) and carefully monitored for several days.
In acute treatments administered during electrophysiological recordings, mice
received Sodium Nitroprusside (SNP; Sigma Aldrich), Phenylephrine (Phe; Sigma
Aldrich) and Hexamethonium bromide (Sigma Aldrich) at the dosage indicated in
the appropriate section.
A cohort of mice received 0.5mg kg 1day 1 of AngiotensinII (AngII;
Sigma Aldrich) or Vehicle (NaCl 0.9%), delivered subcutaneously with osmotic
minipumps (model 2004, ALZET)7. Another group of mice underwent
subcutaneous implantation of a 50-mg pellet of DOCA or placebo as control
(Innovative Research of America) without uninephrectomy23. Mice were
maintained on standard chow with ad libitum access to tap water and 0.15mol l 1
(0.9%) NaCl.
Electrophysiological recording. In the first set of experiments, SSNA was
recorded in mice at maximum blood pressure response to either sodium
nitroprusside or phenylephrine, and in the next set of experiments, SSNA was
recorded three days after receiving either AngII or DOCA-salt. Mice infused with
vehicle or implanted with a placebo pellet were used as respective controls. Mice
were anaesthetized with 5% isoflurane and subsequently maintained with 1.5–2%
(supplemented with 1 lmin 1 oxygen). Blood pressure was monitored during the
entire experiment with a single-pressure catheter (Millar, SPR-100) inserted in the
left femoral artery and connected to a pressure transducer (Millar, MPVS
ULTRA)7. Body temperature was maintained between 37 and 38 C by a
homoeothermic blanket.
An abdominal incision was made and the intestinal tract was carefully moved
aside to expose the splenic artery. First, the splenic artery was isolated, and then the
splenic nerve was carefully separated from surrounding tissue. A bipolar stainless
steel electrode (MLA1214 Spring Clip Electrodes, ADInstruments) was adjusted to
the nerve size and gently placed on the splenic nerve, according to previously
described procedures20–22,38. The ground wire was plugged into mouse soft tissues.
When optimum recording was obtained, the electrode was covered with silicone
gel. SSNA was recorded from the implanted electrode continuously during the next
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Figure 7 | Establishment of a procedure for selective splenic denervation.
(a) Example of surgical procedure for selective SDN, showing the splenic
artery before (upper panel) and after (lower panel) denervation in a
representative animal. (b) Ultrasound Doppler imaging showing a normal
pulse wave of the splenic artery in splenic denervated mice, comparable to
that of sham. Colour Doppler also indicate a normal perfusion of the spleen
after denervation. (c) Anatomical transversal reconstruction of microCT
angiography evidencing of correct uptake of the contrast agent in the
spleen. (d) 3D reconstruction demonstrating integrity of splenic artery after
denervation and consequent normal perfusion of the spleen.
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2 h, as was arterial blood pressure. Mice were then killed by isofluorane overdose,
and SSNA was recorded for a further 30 minutes to estimate postmortem residual
activity.
The splenic nervous signal was amplified (gain 10,000) and then sampled at
4 kHz with a digital amplifier (Animal Bio Amp; ADInstruments). The raw signal
was filtered at 300–1,000 Hz and expressed as mV. Background noise estimates for
the nerve activity trace were based on postmortem recording. Raw splenic nerve
activity and blood pressure signals were monitored using a PC that was online
during the entire recording. Operators were blinded to the experimental group
during recording.
Data were collected using a Power Lab data acquisition system and analyzed
with Lab Chart 7 (Spike Analysis Module). Typically, a sympathetic burst was
identified as a signal above the threshold determined by the background noise of
the postmortem recording. In acute experiments, SSNA counting was measured
using a bin time of 5min at the plateau of blood pressure response after a bolus of
sodium nitroprusside (2.5mg g 1 of body weight in a volume of 25ml of saline
followed by 50ml of saline) or phenylephrine (20 mg g 1 of body weight in a
volume of 25 ml of saline followed by 50ml of saline)20. Background noise was
recorded after ganglionic blockade with hexamethonium20 (50 mg g 1 of body
weight in 25 ml) and during postmortem. In chronic experiments, SSNA counting
was performed using a bin time of 10 min and collected every 20 min. Firing
frequency was measured as the mean value of total number of spikes in a time bin.
The amplitude gain was calculated as the ratio between mean spike amplitude and
spike identification threshold in a time bin.
Vagotomy. Surgical cervical unilateral vagotomy was performed via a cervical
midline incision that exposed the left vagus trunk, which was cut with forceps.
Coeliac vagotomy was performed with the same procedure, cutting the distal end of
the coeliac branch of the vagus nerve. In a first set of experiments, both procedures
were executed while recording SSNA. Vagus nerve was exposed while preparing the
mouse for the electrophysiological recording. After the acquisition of two SSNA
time bins, the cervical or coeliac vagus nerve was transected, while SSNA recording
continued for at least two additionally time bins. In a second group of mice, coeliac
vagotomy was performed and AngII minipumps implanted subcutaneously for
chronic experiments.
Splenic denervation. After anaesthesia with isoflurane (2–5Vol%), supplemented
with 1 lmi 1n oxygen, the mouse abdominal cavity was opened and the splenic
artery was carefully exposed. The selective SDN was performed by thermoablation
applied with a thermal cautery (GEIGER Medical Technologies). The cautery was
gently placed on the splenic artery for 5–6 s until the splenic artery was dilated. In
sham-operated mice, the abdomen was opened and the splenic artery was exposed,
but thermoablation was not performed.
Neurotracer injection. The efficacy of splenic nerve ablation was evaluated by
neuronal labelling, obtained by retrograde transport, in coeliac ganglion. Mice were
anaesthetized with isoflurane (2–5Vol%), the spleen was exposed through a left
flank incision and 10 injections of 2 ml hydroxystilbamidine, methanesulfonate 2%
(Molecular Probes, H22845) were injected into the parenchyma7. Mice were
allowed to recover, and seven days later they were deeply anaesthetized so that
coeliac ganglia from each side could be collected.
Blood pressure measurements. Arterial blood pressure was monitored by
radiotelemetry where indicated. HD-X11 pressure transmitters (Data Sciences
International) were implanted in mice anaesthetized with isofluorane. The
pressure-sensing catheter was inserted into the aortic arch, and the transmitter
body was placed in a subcutaneous pouch on the back. Following surgery, the mice
were allowed to recover for at least 1 week. Radio signals from the implanted
transmitter were captured by the Physiotel RPC-1 receiver (Data Sciences
International), and the data were stored online using the Dataquest Ponemah
4.9 data acquisition system (Data Sciences International) according to standardized
procedures7,39,40. BP was recorded daily for 2 h (10am-12pm) to monitor the
effects of AngII.
Noninvasive blood pressure measurement was performed by tail-cuff
plethysmography (BP-2000 Series II, Visitech Systems) in conscious mice daily for
2 hours (10 am–12 pm)7,39,40. Operators were blinded to the experimental group
during blood pressure monitoring.
In vivo imaging. Ultrasound analysis was performed with Vevo 2100 (VisualSo-
nics, Toronto, Canada) equipped with 40MHz transducer, as previously described7.
Mice were anaesthetized with isoflurane anaesthesia system (5Vol% induction,
1.5 Vol% maintenance supplemented with 1 lmin 1 oxygen) and taped to a
warmed bed, positioned on the right side. The spleen area was shaved, and the
probe was positioned under the chest to get a longitudinal view of the spleen.
To visualize splenic artery perfusion and function after splenic denervation, PW
Doppler was applied in order to measure peak flow velocity. Colour Doppler was
applied to images of the spleen to verify organ perfusion after splenic denervation.
MicroCT scanning was performed with SKYSCAN 1178 (SKYSCAN, Kontich,
Belgium), as previously described7. The tube parameters were set to 50 kV and 615
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Figure 8 | Selective splenic denervation blocks sympathetic nervous system in the spleen. (a) Coeliac ganglion neurons, labelled with a retrograde
neurotracer injected in the splenic parenchyma, are significantly reduced in SDN mice as compared with sham controls. (nmice¼6 for each group; scale bar,
200mm). (b) Significant reduction of tyrosine hydroxylase immunofluorescence in splenic artery of two representative SDN as compared with Sham mice
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mA, exposure 480ms, with a rotation step of 0.360. Mice were anaesthetized with
ketamine-xylazine and positioned on the bed. Two different scans were performed:
the first scan occurred immediately after contrast agent injection (ExiTron nano
12,000, 100 ml per mouse) to determine vascular perfusion; after 24 h, the second
scan was performed to obtain a spleen tissue image using contrast agent
accumulation in the spleen. Spleen reconstruction was performed with 3D Slicer41.
In both scans, the image was cropped to the spleen region, then the images were
co-registered with an affine transformation. The co-registered images were labelled
and 3D rendered to highlight the vascularization in the first scan (shown in red)
and contrast tissue absorption (shown in green) in the second scan.
Tissue isolation. At the end of each experiment, tissues were isolated for
subsequent analyses. The splenic artery was isolated and fixed with
4% paraformaldehyde (PFA). Spleen and aorta were collected and embedded in
OCT for cryo-sectioning. Kidneys were explanted and embedded in paraffin for
immunohistochemistry. Coeliac ganglion was post-fixed in Zamboni’s Fixative and
embedded in OCT for cryo-sectioning. For biochemical analyses, spleen and
kidneys were explanted and flash-frozen in liquid nitrogen.
Flow cytometry. After mice were exsanguinated, both kidney and aorta were
collected. Kidney cell suspension was obtained by mechanically disrupting two
decapsulated kidneys in 10 ml of RPMI 1640 medium (GIBCO, Invitrogen)
supplemented with 5% FBS, which was then passed through a 70 mm sterile filter
(Falcon, BD). The resulting cell suspension was centrifuged at 300g for 10 min to
pellet the cells. To isolate leukocytes from cell suspension, the pellet was suspended
in 36% Percoll (Sigma), gently overlaid onto 72% Percoll and centrifuged at 1,000g
for 30 min at RT. Cells were isolated from Percoll interface and washed twice in
medium at 300g for 10 min at 4 C. Aorta cell suspension was obtained by
mechanically disrupting the tissue and digesting the suspension in Digestion
Cocktail (450Uml 1 Collagenase I, 125Uml 1 Collagense XI, 60Uml 1
Hyaluronidase I-S) for 40 min at 37 C with gentle vortexing. Cell suspension was
then passed through a 70 mm sterile filter (Falcon, BD), and the resulting cell
suspension was centrifuged at 300g for 5 min to pellet the cells.
Lymphocytes from both organs’ leukocytes were enriched with Mouse
T Lymphocyte Enrichment Set-DM (BD IMag), and the number of the cells
was assessed using trypan blue and an automated counter (Countess, Life
Technologies). Total kidney and aorta lymphocytes were analyzed with flow
cytometry. First, samples were pre-incubated with anti CD-16/32 Fc receptor and
then incubated with various combinations of mAbs for immunofluorescence
staining using BD FACSCanto (BD Biosciences). The fluorochrome-conjugated
mAbs to mouse antigens used for flow cytometry analysis were as follows:
PerCP-Cy5.5 anti-CD8a (53-6.7), FITC anti-CD4 (RM4-5), APC anti-CD69
(H1.2F3), APC-Cy7 anti-CD45 (30-F11), PE-Cy7 anti-CD44 (IM7) (1:100;
BD PharMingen). The data were analyzed using FlowJo Software (V 10.0.8).
D
AP
i C
D3
 
B2
20
D
AP
i C
D8
6 
CD
16
9 
160
150
140
130
120
110
100
100
90
80
90
80
70
60
50
40
0 4 8 12 16 20 24 28
Days
Ve
hi
cl
e
Vehicle
28 days AngII
An
gI
I
0 4 8 12 16 20 24 28
Days
180
150
120
90
Ar
ea
 o
f C
D3
+
 
T*
10
3
μm
2
60
30
0
***
***
AngII AngII
Sham AngII
Sham vehicle
Sham SDN
Ve
hi
cl
e
An
gI
I
Sham SDN
Sham SDN
SDN vehicle
SDN AngII
Sham AngII
Sham vehicle
SDN vehicle
SDN AngII
*** ***
SB
P 
(m
mH
g)
D
BP
 (m
mH
g)
a b
c
d
e
Figure 9 | Splenic denervation protects from hypertension and T cell egression from spleen. (a,b) Mice with splenic denervation were protected from
AngII-induced hypertension, as compared with Sham mice and SDN mice with vehicle alone (Sham-vehicle, Sham-AngII and SDN-vehicle nmice¼ 10;
SDN-AngII nmice¼ 11; two-way ANOVA for repeated measures; (a) SBP, F(interaction)¼ 6.723, ***Po0.001; (b) DBP, F(interaction)¼ 3.070, ***Po0.001).
(c) Mice with splenic denervation are protected from the Tcell egression induced by AngII, as evidenced by the area of CD3þ cells (magenta), recognizing
white pulp and delimited by B220þ cells (green) delineating red pulp (nmice¼ 5 for each group; scale bar, 200mm). (d) Graph showing the relative
quantitative analysis (nmice¼ 5 for each group; two-way ANOVA, F(interaction)¼46.384, ***Po0.001). (e) AngII fails to induce co-stimulation of T cells in
mice with splenic denervation, as evidenced by reduced CD86þ cells (green) expression in the marginal zone of the spleen, labelled by CD169þ cells
(magenta) (nmice¼ 5 for each group; scale bar, 50mm).
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms13035
10 NATURE COMMUNICATIONS | 7:13035 | DOI: 10.1038/ncomms13035 | www.nature.com/naturecommunications
40
30
20
10
10
15
5
0
10
15
20
5
0
10
10
8
6
4
2
0
10
8
6
4
2
0
10
8
6
4
2
0
15
5
0
0
Sham SDN
Sham SDN Sham SDN Sham SDN Sham SDN
Sham SDNSham SDNSham SDNSham SDN
Sham SDN
***
***
***
***
***
***
*
*
*
**
*
**
***
***
Sham SDN Sham SDN
***
Aorta Kidney
**
**
**
**
**
***
**
***
**
CD
8+
 *
 1
03
 
ce
lls
CD
8+
CD
44
+
 *
 1
03
 
ce
lls
CD
8+
CD
69
+
 *
 1
03
 
ce
lls
10
15
20
5
0CD
4+
CD
69
+
 *
 1
03
 
ce
lls
CD
8+
CD
69
+
 *
 1
03
 
ce
lls 10
8
6
4
2
0CD
4+
CD
69
+
 *
 1
03
 
ce
lls
CD
4+
CD
44
+
 *
 1
03
 
ce
lls
CD
8+
CD
44
+
 *
 1
03
 
ce
lls
CD
4+
CD
44
+
 *
 1
03
 
ce
lls
40 Vehicle
28 days AngII
Vehicle
28 days AngII
40
60
30
20
20
10
0 0
40
60
20
0
CD
4+
 *
 1
03
 
ce
lls
CD
8+
 *
 1
03
 
ce
lls
CD
4+
 *
 1
03
 
ce
lls
Sham AngII SDN AngII
CD4 subset
CD8 subset
CD4 subset
CD8 subset
105
105
104
104
105104
103
103
–103
–103
Co
m
p-
FI
TC
-A
 ::
 C
D4
Co
m
p-
PE
-C
y7
-A
 ::
 C
D4
Comp-PerCP-Cy5-5-A :: CD8
Comp-FITC-A :: CD4
0
105
104
103
–103
0
Co
m
p-
AP
C-
A 
:: 
CD
69 105
104
103
–103
0
Co
m
p-
PE
-C
y7
-A
 ::
 C
D4
Co
m
p-
PE
-C
y7
-A
 ::
 C
D4
4
Co
m
p-
PE
-C
y7
-A
 ::
 C
D4
4105
104
103
–103
0
105
104
103
–103
0
105
104
103
–103
0
105
104
103
–103
Co
m
p-
FI
TC
-A
 ::
 C
D4
0
0
0
105104
Comp-FITC-A :: CD4
0
105104
Comp-PerCP-Cy5-5-A :: CD8 Comp-FITC-A :: CD4
0
Co
m
p-
AP
C-
A 
:: 
CD
69 105
104
103
–103
0
105104
Comp-PerCP-Cy5-5-A :: CD8
0
1051040
Co
m
p-
AP
C-
A 
:: 
CD
69
Co
m
p-
AP
C-
A 
:: 
CD
69105
104
103
–103
0
105
104
103
–103
0
Comp-FITC-A :: CD4
1051040
Comp-PerCP-Cy5-5-A :: CD8
1051040
Comp-PerCP-Cy5-5-A :: CD8
1051040
105104103–103
Comp-PerCP-Cy5-5-A :: CD8
0
a b
c
CD4-CD44 subset
CD8-CD44 subset
CD4-CD44 subset
CD8-CD44 subset
CD8-CD69 subsetCD4-CD69 subset
CD8-CD69 subsetCD4-CD69 subset
Figure 10 | Splenic denervation protects from the T cells infiltration in target organs of hypertension. (a,b) Flow cytometry analysis shows that
SDN mice were protected from the AngII-induced increase of total CD8þ and CD4þ T cells (upper panels) in aorta (a) and (b) kidneys. SDN mice
displayed also a reduced amount of cells positive for homing (CD44) and activation (CD69) antigens (middle and lower panels, respectively) (nmice¼9 for
each group). Significance of two-way ANOVA was as follow for aortas: CD8 F(interaction)¼ 7.922, CD8-CD44 F(interaction)¼ 5.071, CD8-CD69
F(interaction)¼ 7.344, CD4 F(interaction)¼9.122, CD4-CD44 F(interaction)¼ 7.867, CD4-CD69 F(interaction)¼ 8.432. Significance of Two-way ANOVA was as
follow for kidneys: CD8 F(interaction)¼ 13.88, CD8-CD44 F(interaction)¼ 5.382, CD8-CD69 F(interaction)¼ 7.202, CD4 F(interaction)¼ 6.248, CD4-CD44
F(interaction)¼ 3.810, CD4-CD69 F(interaction)¼ 10.89. *Po0.05, **Po0.01 and ***Po0.001. (c) Representative plots and gating strategies are shown for
kidneys.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms13035 ARTICLE
NATURE COMMUNICATIONS | 7:13035 | DOI: 10.1038/ncomms13035 | www.nature.com/naturecommunications 11
Immunofluorescence analysis. Splenic arteries used for immunofluorescence
analysis were fixed with 4% PFA, passed in PBS for incubation with antibodies and
then coverslipped with anti-fading medium (DABCO, Fluka). For coeliac ganglion
and spleen, 25 mm sections were obtained with cryostat microtome. Coeliac
ganglions were directly mounted and coverslipped for analysis of neurons labelled
with retrograde fluorescent neurotracer. Slides from the spleen were post-fixed in
PFA (4%) for 15 min and processed for staining.
The following primary antibodies were used: Sheep anti-tyrosine hydroxylase
(1:800; AB1542, Millipore); Rat anti-CD169 (1:200; MCA884, Serotec); Hamster
anti-CD3 (1:100; MCA269OT, Serotec); Rat anti-CD45R/B220 (1:50; 550286, BD
Pharmigen); Rabbit anti-CD86 (1:100; NB110-55488, Novus Biologicals). Sections
were incubated with their respective secondary antibodies conjugated to Alexa
Fluor 488 or Cy3 (1:200; Jackson Immunoresearch). Slides were then coverslipped
with DAPI-containing medium (Vector).
All coverslipped, mounted tissue sections were scanned using a Zeiss 780
confocal laser-scanning microscope, as previously described7. A 405 Diode laser
was used to excite DAPI; a 488 nm argon laser to excite Alexa Fluor 488 and a 543
HeNe to excite Cy3. Quantitative analyses were determined using Image J software
(NIH).
Immunohistochemistry analysis. Kidney sections were deparaffinized and
rehydrated before undergoing antigen retrieval. Aortas, embedded in OCT, were
post-fixed with PFA (4%) for 15 minutes. Slides were processed with the primary
antibodies anti-CD8 (1:50; 550286, BD PharMingen) and anti-CD4 (1:50; 550280,
BD PharMingen). Samples were incubated with biotinylated secondary antibodies
(1:200; Vector) and then processed with DAB (Vector). Hematoxylin (Sigma
Aldrich) was used for counterstaining. The number of CD8þ and CD4þ cells per
mm2 was determined using the Image J software Cell Counter plugin analysis tool
(NIH). All images were captured using a DMI3000B Leica optical microscope
provided by Leica Cameras (Leica Microsystems) and processed with the Leica
Application Suite (LAS V3.3).
ELISA for noradrenaline assay. Noradrenaline levels were measured in duplicate
for each spleen and kidney sample. Samples were extracted with a buffer containing
0.1 HCl and 1 mM EDTA and assayed using a high-sensitivity ELISA kit (RE59261,
IBL International), following the manufacturer’s instructions. Results are expressed
as nmolmg 1 of wet tissue.
Statistical analysis. All the experiments were replicated within the laboratory.
Sample size was pre-estimated from the previously published research and from
pilot experiments performed in the laboratory. Data are presented as mean±s.e.m.
Data distribution was assessed with the Shapiro–Wilk normality test and
D’Agostino Pearson test, and assumption of homogeneity of variance was tested
using Levene’s test of equality of variances. For amplitude gain analysis, unequal
variance between groups was observed in a minority of cases, and a Welch
correction was performed for all comparisons. Statistical significance was assessed
with the appropriate test according to each experimental design, as detailed in
figure legends. After confirming that all data had normal distributions, we applied
Student t-test for either independent samples or paired samples, according to the
experimental design and as specified in the figure legends. Multiple group analysis
was performed with two-way ANOVA followed by Bonferroni’s post hoc. Analysis
for repeated measures was applied when required by the experimental setting.
Po0.05 was considered significant. Statistical analyses were performed with SPSS
23.0 (IBM Software) and graphs were made with GraphPad Software PRISM5.
Data availability. The authors declare that all other data supporting the findings
of this study are available within the article and its Supplementary Information files
and from the corresponding authors upon request.
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